{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:49:35Z","timestamp":1767844175104,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12954-019-0316-4","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T14:08:54Z","timestamp":1563199734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Introducing hepatitis C virus healthcare pathways in addiction care in the Netherlands with a Breakthrough project: a mixed method study"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5794-9386","authenticated-orcid":false,"given":"Patricia A. M.","family":"Kracht","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth A.","family":"de Gee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc A. M. T.","family":"Verhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy I. M.","family":"Hoepelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther A.","family":"Croes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joop E.","family":"Arends","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"316_CR1","volume-title":"Drugs binnen de grenzen; harddrugs en criminaliteit in Nederland: schattingen van de omvang","author":"B Bieleman","year":"1995","unstructured":"Bieleman B, Snippe J, de Bie E. Drugs binnen de grenzen; harddrugs en criminaliteit in Nederland: schattingen van de omvang. Groningen: Intraval (bureau voor onderzoek & advies); 1995."},{"key":"316_CR2","volume-title":"Netherlands National Drug Monitor: NDM Annual Report 2002","author":"M van der Laar","year":"2002","unstructured":"van der Laar M, Cruts A, Rigter H, Verdurmen J, Meijer R, van Ooyen M, et al. Netherlands National Drug Monitor: NDM Annual Report 2002. Utrecht: Bureau NDM - Trimbos Instituut; 2002."},{"issue":"10","key":"316_CR3","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.2105\/AJPH.79.10.1355","volume":"79","author":"JA van den Hoek","year":"1989","unstructured":"van den Hoek JA, van Haastrecht HJ, Coutinho RA. Risk reduction among intravenous drug users in Amsterdam under the influence of AIDS. Am J Public Health. 1989;79(10):1355\u20137.","journal-title":"Am J Public Health."},{"issue":"4902","key":"316_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1126\/science.2523562","volume":"244","author":"QL Choo","year":"1989","unstructured":"Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359\u201362.","journal-title":"Science."},{"issue":"4902","key":"316_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1126\/science.2496467","volume":"244","author":"G Kuo","year":"1989","unstructured":"Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989;244(4902):362\u20134.","journal-title":"Science."},{"issue":"9","key":"316_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","volume":"10","author":"B Hajarizadeh","year":"2013","unstructured":"Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553\u201362.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"1","key":"316_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1477-7517-7-25","volume":"7","author":"I Schreuder","year":"2010","unstructured":"Schreuder I, van der Sande MA, de Wit M, Bongaerts M, Boucher CA, Croes EA, et al. Seroprevalence of HIV, hepatitis b, and hepatitis c among opioid drug users on methadone treatment in the Netherlands. Harm Reduct J. 2010;7(1):25.","journal-title":"Harm Reduct J."},{"issue":"1","key":"316_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/MEG.0b013e328340c451","volume":"23","author":"CEA Lindenburg","year":"2011","unstructured":"Lindenburg CEA, Lambers FAE, Urbanus AT, Schinkel J, Jansen PLM, Krol A, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol. 2011;23(1):23\u201331.","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"4","key":"316_CR9","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/infdis\/162.4.823","volume":"162","author":"JA van den Hoek","year":"1990","unstructured":"van den Hoek JA, van Haastrecht HJ, Goudsmit J, de Wolf F, Coutinho RA. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis. 1990;162(4):823\u20136.","journal-title":"J Infect Dis."},{"issue":"3","key":"316_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1017\/S0950268812000921","volume":"141","author":"M Rondy","year":"2013","unstructured":"Rondy M, Wiessing L, Hutchinson SJ, Mathe\u00ef C, Mathis F, Mravcik V, et al. Hepatitis C prevalence in injecting drug users in Europe, 1990\u20132007: impact of study recruitment setting. Epidemiol Infect. 2013;141(3):563\u201372.","journal-title":"Epidemiol Infect."},{"key":"316_CR11","doi-asserted-by":"crossref","unstructured":"van Santen DK, van der Helm JJ, Lindenburg K, Schim van der Loeff M, Prins M. HIV and hepatitis C treatment uptake among people who use drugs participating in the Amsterdam Cohort Studies, 1985\u20132015. Int J Drug Policy. 2017;47:95\u2013101.","DOI":"10.1016\/j.drugpo.2017.05.026"},{"issue":"2","key":"316_CR12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/hep.22375","volume":"48","author":"H-H Thein","year":"2008","unstructured":"Thein H-H, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418\u201331.","journal-title":"Hepatology."},{"issue":"11","key":"316_CR13","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1111\/j.1572-0241.2003.07678.x","volume":"98","author":"B Goodgame","year":"2003","unstructured":"Goodgame B, Shaheen NJ, Galanko J, El-Serag HB. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol. 2003;98(11):2535\u201342.","journal-title":"Am J Gastroenterol."},{"issue":"4","key":"316_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/jmv.20486","volume":"77","author":"TJW van de Laar","year":"2005","unstructured":"van de Laar TJW, Langendam MW, Bruisten SM, Welp EAE, Verhaest I, van Ameijden EJC, et al. Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands. J Med Virol. 2005;77(4):509\u201318.","journal-title":"J Med Virol."},{"issue":"9","key":"316_CR15","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/j.1360-0443.2007.01912.x","volume":"102","author":"C Van Den Berg","year":"2007","unstructured":"Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M, Amsterdam Cohort. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction. 2007;102(9):1454\u201362.","journal-title":"Addiction."},{"key":"316_CR16","volume-title":"Sexually transmitted infections including HIV, in the Netherlands in 2016","author":"M Visser","year":"2017","unstructured":"Visser M, van Aar F, van Oeffelen A, van den Broek I, op de Coul E, Hofstraat S, et al. Sexually transmitted infections including HIV, in the Netherlands in 2016. Bilthoven: National Institute for Public Health and the Environment (RIVM) Rep 2017-0003; 2017."},{"key":"316_CR17","volume-title":"Kerncijfers Verslavingszorg 2015","author":"DJ Wisselink","year":"2016","unstructured":"Wisselink DJ, Kuijpers WGT, Mol A. Kerncijfers Verslavingszorg 2015. Houten: Landelijk Alcohol en Drugs Informatie Systeem (LADIS); 2016."},{"key":"316_CR18","volume-title":"Richtlijn Opiaatonderhoudsbehandeling (RIOB). Herziene versie","author":"C Loth","year":"2012","unstructured":"Loth C, Wits E, Jong de C, Mheen van de D. Richtlijn Opiaatonderhoudsbehandeling (RIOB). Herziene versie. Resultaten Scoren: Amersfoort; 2012."},{"key":"316_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.drugpo.2017.07.022","volume":"47","author":"CW Helsper","year":"2017","unstructured":"Helsper CW, Janssen MP, van Essen GA, Croes EA, van der Veen C, de Wit AG, et al. Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands. Int J Drug Policy. 2017;47:117\u201325.","journal-title":"Int J Drug Policy."},{"issue":"4","key":"316_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00019514-199806040-00001","volume":"6","author":"CM Kilo","year":"1998","unstructured":"Kilo CM. A framework for collaborative improvement: lessons from the Institute for Healthcare Improvement\u2019s Breakthrough Series. Qual Manag Health Care. 1998;6(4):1\u201313.","journal-title":"Qual Manag Health Care"},{"key":"316_CR21","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.5334\/ijic.314","volume":"9","author":"G Franx","year":"2009","unstructured":"Franx G, Meeuwissen JAC, Sinnema H, Spijker J, Huyser J, Wensing M, et al. Quality improvement in depression care in the Netherlands: the Depression Breakthrough Collaborative. A quality improvement report. Int J Integr Care. 2009;9:e84.","journal-title":"Int J Integr Care."},{"issue":"2","key":"316_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1046\/j.1523-536x.1998.00117.x","volume":"25","author":"BL Flamm","year":"1998","unstructured":"Flamm BL, Berwick DM, Kabcenell A. Reducing cesarean section rates safely: lessons from a \u201cbreakthrough series\u201d collaborative. Birth. 1998;25(2):117\u201324.","journal-title":"Birth."},{"issue":"7","key":"316_CR23","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S1553-7250(05)31052-X","volume":"31","author":"DJ Katzelnick","year":"2005","unstructured":"Katzelnick DJ, Von Korff M, Chung H, Provost LP, Wagner EH. Applying depression-specific change concepts in a collaborative breakthrough series. Jt Comm J Qual patient Saf. 2005;31(7):386\u201397.","journal-title":"Jt Comm J Qual patient Saf."},{"key":"316_CR24","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1097\/QAD.0000000000000716","volume":"29","author":"CM Horwood","year":"2015","unstructured":"Horwood CM, Youngleson MS, Moses E, Stern AF, Barker PM. Using adapted quality-improvement approaches to strengthen community-based health systems and improve care in high HIV-burden sub-Saharan African countries. AIDS. 2015;29:S155\u201364.","journal-title":"AIDS."},{"key":"316_CR25","volume-title":"Het kleine zorgpaden handboek voor de GGZ","author":"M de Jong","year":"2012","unstructured":"de Jong M, Schaap-Visser A, van Fulpen A. Het kleine zorgpaden handboek voor de GGZ. Woerden: CC Zorgadviseurs; 2012."},{"key":"316_CR26","volume-title":"Het zorgpadenboek: voorbeelden van goede ziekenhuiszorg","author":"N Huiskes","year":"2011","unstructured":"Huiskes N, Schrijvers G. Het zorgpadenboek: voorbeelden van goede ziekenhuiszorg. Amsterdam: Thoeris; 2011."},{"key":"316_CR27","unstructured":"The European Pathway Association (E-P-A). Care pathways [cited 2018 May 4]. Available from: \n                    http:\/\/e-p-a.org\/care-pathways\/"},{"issue":"3","key":"316_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1258\/095148407781395964","volume":"20","author":"K Vanhaecht","year":"2007","unstructured":"Vanhaecht K, De Witte K, Depreitere R, Van Zelm R, De Bleser L, Proost K, et al. Development and validation of a care process self-evaluation tool. Heal Serv Manag Res. 2007;20(3):189\u2013202.","journal-title":"Heal Serv Manag Res."},{"key":"316_CR29","volume-title":"QSR International Pty Ltd. Version 11","author":"NVivo qualitative data analysis Software","year":"2017","unstructured":"NVivo qualitative data analysis Software. QSR International Pty Ltd. Version 11, 2017."},{"key":"316_CR30","volume-title":"Hepatitis C in de verslavingszorg. De effectiviteit van de hepatitis C informatiecampagne","author":"E Croes","year":"2012","unstructured":"Croes E, van der Veen C. Hepatitis C in de verslavingszorg. De effectiviteit van de hepatitis C informatiecampagne. Utrecht: the Netherlands Institute of Mental Health and Addiction (Trimbos Institute); 2012."},{"key":"316_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugpo.2017.07.002","volume":"47","author":"S Bajis","year":"2017","unstructured":"Bajis S, Dore GJ, Hajarizadeh B, Cunningham EB, Maher L, Grebely J. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review. Int J Drug Policy. 2017;47:34\u201346.","journal-title":"Int J Drug Policy."},{"issue":"1","key":"316_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12916-019-1300-2","volume":"17","author":"HR Stagg","year":"2019","unstructured":"Stagg HR, Surey J, Francis M, MacLellan J, Foster GR, Charlett A, et al. Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention. BMC Med. 2019;17(1):71.","journal-title":"BMC Med."},{"issue":"6","key":"316_CR33","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/add.14569","volume":"114","author":"GI Harrison","year":"2019","unstructured":"Harrison GI, Murray K, Gore R, Lee P, Sreedharan A, Richardson P, et al. The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England. Addiction. 2019;114(6):1113\u201322.","journal-title":"Addiction."},{"issue":"2","key":"316_CR34","first-page":"147","volume":"63","author":"B Denis","year":"2000","unstructured":"Denis B, Dedobbeleer M, Collet T, Petit J, Jamoulle M, Hayani A, et al. High prevalence of hepatitis C virus infection in Belgian intravenous drug users and potential role of the \u201ccotton-filter\u201d in transmission: the GEMT Study. Acta Gastroenterol Belg. 2000;63(2):147\u201353.","journal-title":"Acta Gastroenterol Belg."},{"issue":"6","key":"316_CR35","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1365-2893.2005.00643.x","volume":"12","author":"A Judd","year":"2005","unstructured":"Judd A, Hutchinson S, Wadd S, Hickman M, Taylor A, Jones S, et al. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. J Viral Hepat. 2005;12(6):655\u201362.","journal-title":"J Viral Hepat."},{"issue":"1","key":"316_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1017\/S0950268804002973","volume":"133","author":"C Mathe\u00ef","year":"2005","unstructured":"Mathe\u00ef C, Robaeys G, van Damme P, Buntinx F, Verrando R. Prevalence of hepatitis C in drug users in Flanders: determinants and geographic differences. Epidemiol Infect. 2005;133(1):127\u201336.","journal-title":"Epidemiol Infect."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-019-0316-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-019-0316-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-019-0316-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T23:22:49Z","timestamp":1594682569000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-019-0316-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["316"],"URL":"https:\/\/doi.org\/10.1186\/s12954-019-0316-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,15]]},"assertion":[{"value":"31 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no ethical conflicts to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Arends reports University fees from AbbVie, BMS, Gilead, Janssen, MSD, and ViiV and (research) grants from AbbVie and BMS, outside the submitted work. Dr. Hoepelman reports personal fees from AbbVie, BMS, Gilead, and Janssen. Trimbos Institute received co-financing from AbbVie, Gilead, Janssen, MSD, and Roche and also from the Ministry of Health Welfare and Sports and ZonMW for the HAC Breakthough projects. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}